Latest news

• NICE rejects Akcea’s rare inherited disorder drug Waylivra

  Waylivra (volanesorsen) is an antisense drugs, used for the treatment of a rare inherited disorder called familial chylomicronemia syndrome (FCS). ... As a patient-focused company, we are dedicated to supporting patients with FCS and those patients who

• Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

  roll-out stage for two new products, Tegsedi (inotersen) for hereditary transthyretin-mediated amyloidosis and  Waylivra (volanesorsen) for familial chylomicronemia syndrome (FCS).

• Akcea gets first OK for Waylivra in rare triglyceride disorder

  The European Commission has cleared Waylivra (volanesorsen) as an adjunct to diet in adult patients with confirmed FCS who are at high risk for pancreatitis and have not responded well enough

• Akcea steals march on Alnylam with NICE approval

  NICE’s ruling adds to the good news for Akcea, which in March gained a CHMP recommendation for Waylivra (volanesorsen), which would be its second drug to reach market.

• CHMP backs Lynparza in breast cancer, Dupixent in asthma

  The committee recommended a conditional marketing approval for Akcea’s Waylivra (volanesorsen) for the treatment of the familial chylomicronaemia syndrome (FCS), a genetic disease that prevents the body from breaking down